Anti-LRRK2 (Leucine-rich repeat kinase 2)

Description:
Parkinson’s disease (PD), the second most common neurodegenerative disease after Alzheimer’s, is a progressive movement disorder characterized by rigidity, tremors and postural instability. The pathological hallmark of PD is progressive loss of dopaminergic neurons in the substantia nigra of the ventral midbrain and the presence of intracellular Lewy bodies (protein aggregates of α-synuclein, ubiquitin and other components) in surviving neurons of the brain stem (1). Various genes and loci (α-synuclein/PARK1 and 4, parkin/PARK2, UCH-L1/PARK5, PINK1/PARK6, DJ-1/PARK7, LRRK2/PARK8, synphilin-1 and NR4A2) are genetically linked to PD.Leucine-rich repeat kinase 2 (LRRK2) contains amino-terminal leucine-rich repeats (LRR), a Ras-like small GTP binding protein-like (ROC) domain, a MLK protein kinase domain and carboxy-terminal WD40-repeat. At least 20 LRRK2 mutations have been linked to PD, the G2019S mutation being the most prevalent. The G2019S mutation causes increased LRRK2 kinase activity, which induces a progressive reduction in neurite length, leading to progressive neurite loss and decreased neuronal survival. The MLK inhibitor CEP-1347 is explored in PD clinical trials indicating that LRRK2 may have value as a therapeutic target for treatment of PD.

Storage: Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.